Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003983 | 0.74 | NR1H2 (0.39) | GPR119NR1H2NR1H3 | |
| SCHEMBL4832476 | 0.72 | USP30 (0.40) | ACKR3TRPV3ENPP2GPR119USP30 | |
| SCHEMBL4760698 | 0.71 | ACKR3 (0.48) | ACKR3ENPP2F2RL1 | |
| SCHEMBL28479279 | 0.71 | GPR119 (0.43) | GPR119TP53USP30 | |
| SCHEMBL21360346 | 0.70 | GRM5 (0.42) | TRPV3CNR1GPR119NR1H2TP53 | |
| SCHEMBL6004463 | 0.69 | ACKR3 (0.36) | ACKR3ENPP2EGFRGPR119TP53 | |
| SCHEMBL6002680 | 0.68 | USP30 (0.40) | ACKR3TRPV3ENPP2EGFRADORA2A | |
| SCHEMBL4761763 | 0.67 | ACKR3 (0.41) | ACKR3ADORA2AADORA2BCNR1CNR2 | |
| SCHEMBL4791362 | 0.67 | ACKR3 (0.41) | ACKR3TRPV3ENPP2CNR1CNR2 | |
| SCHEMBL6679386 | 0.67 | HCRTR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ACKR3 262/4885TRPV3 1893/4885ENPP2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.